


Ask a doctor about a prescription for MIFEGYNE 200 mg TABLETS
Package Leaflet: Information for the User
Mifegyne 200 mg tablets
Mifepristone
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the package leaflet
Mifegyne tablets contain mifepristone, which is an anti-hormone that acts by blocking the effects of progesterone, a hormone necessary for the continuation of pregnancy. Mifegyne can therefore cause the interruption of pregnancy. It can also be used to soften and dilate the entrance to the uterus (cervix).
Mifegyne is recommended for use:
Do not take Mifegyne
For termination of pregnancy up to 63 days after your last menstrual period:
To soften and open the cervix before surgical termination of pregnancy:
For termination of pregnancy after the third month of pregnancy:
Warnings and precautions
Consult your doctor before starting to take Mifegyne
If you are using an intrauterine contraceptive device, it must be removed before taking Mifegyne.
Before taking Mifegyne, you will have a blood test to determine your Rh factor. If you have a negative Rh factor, your doctor will inform you of the usual treatment required.
Severe skin reactions, such as toxic epidermal necrolysis and acute generalized exanthematous pustulosis, have been reported with Mifegyne treatment. Stop using Mifegyne and seek medical attention immediately if you experience any of the symptoms described in section 4. If you experience a severe skin reaction, you should not use mifepristone again in the future.
Other medications and Mifegyne
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those purchased without a prescription.
In particular, inform your doctor if you are taking:
Taking Mifegyne with food and drinks
Do not drink grapefruit juice while being treated with Mifegyne.
Pregnancy, breastfeeding, and fertility
Pregnancy
Failure of pregnancy termination (continuation of pregnancy) after taking Mifegyne alone or in combination with prostaglandin and carrying the pregnancy to term has been associated with congenital defects.
The risk of failure increases:
If pregnancy termination fails after taking this medication or the combination of medications, there is an unknown risk to the fetus. If you decide to continue with this pregnancy, you will need to have close prenatal monitoring with repeated ultrasounds, paying special attention to the limbs, in a specialized clinic. Your doctor will provide more information.
If you decide to continue with pregnancy termination, another method will need to be used. Your doctor will inform you of the options.
Breastfeeding
If you are breastfeeding, consult your doctor before taking this medication. You should stop breastfeeding while taking Mifegyne, as the medication may pass into breast milk.
Fertility
This medication does not affect fertility. You can become pregnant again as soon as the termination is complete. You should start using a contraceptive method immediately after your doctor confirms the termination of pregnancy.
Driving and using machines
Dizziness may occur as a side effect related to the abortion process. Be careful when driving or using machines after taking this medication until you know how Mifegyne affects you.
Follow the administration instructions indicated by your doctor exactly.
In case of doubt, consult your doctor or pharmacist again.
Termination of pregnancy up to 49 days after your last menstrual period
Adult dosage
Tablet intake
Termination of pregnancy between 50 and 63 days after your last menstrual period
Adult dosage
You should take 3 tablets orally.
Tablet intake
This method involves your active participation, and therefore, you must be aware of:
The steps to follow for medical termination of pregnancy are as follows:
Contact the center that prescribed the medication immediately:
Another important aspect to remember:
Uterine bleeding usually starts 1 to 2 days after taking Mifegyne.
In rare cases, expulsion may occur before taking the prostaglandin. It is essential to have a check-up to confirm that the expulsion has been completed; for this, you will need to return to the center where you were treated.
If the pregnancy continues or the expulsion has not been complete, your doctor will inform you of the options to complete the termination of pregnancy.
It is recommended that you do not travel far from the center that prescribed the medication until the follow-up visit.
In case of emergency or if you have any questions, you can contact your center by phone or go to the center. You do not need to wait for your follow-up visit.
Adult dosage
Tablet intake
The steps to follow for medical termination of pregnancy are as follows:
Your doctor will explain the procedure. You may experience bleeding after taking Mifegyne, before the operation.
In rare cases, expulsion may occur before surgery. It is essential to return to the center to confirm that the expulsion has been completed.
You must return to the selected center for surgery. In case of emergency or if you have any questions, you can contact your center by phone or go to the center. You do not need to wait for your follow-up visit.
Adult dosage
Tablet intake
Adult dosage
Tablet intake
Use in adolescents
Only limited data are available on the use of Mifegyne in adolescents.
If you take more Mifegyne than you should
If you take too many tablets, contact your doctor immediately or go to the emergency department of the nearest hospital.
Your doctor will administer the exact amount of Mifegyne; therefore, it is unlikely that you will take too many tablets. Taking too many tablets may cause symptoms of adrenal insufficiency. Signs of acute overdose may require specialist treatment, including the administration of dexamethasone.
In case of overdose or accidental ingestion, consult your doctor or pharmacist or call the Toxicology Information Service. Phone 915 620 420, indicating the medication and the amount used.
If you forget to take Mifegyne
If you forget to follow any part of the treatment, it is likely that the method will not be totally effective. Inform your doctor if you forget to take Mifegyne or the prescribed part of the treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Serious side effects:
Other serious side effects:
If you experience any of these side effects, contact your doctor IMMEDIATELY or go to the emergency department of the nearest hospital.
Other side effects
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are side effects not listed in this package leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
This medication does not require any special storage temperature. Store in the original packaging to protect it from light.
Do not use this medication after the expiration date stated on the box after "EXP". The expiration date is the last day of the month indicated.
Do not use this medication if you notice signs of deterioration in the box or blisters.
Medications should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Mifegyne Composition
A Mifegyne tablet contains 200 mg of mifepristone.
Product Appearance and Package Contents
Mifegyne is presented in the form of light yellow, biconvex tablets, with a diameter of 11 mm and "167 B" engraved on one face.
Mifegyne is available in package sizes of 1, 3 x 1, 15 x 1, or 30 x 1 tablets in precut unit-dose PVC/aluminum blisters.
Not all package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
EXELGYN
216 boulevard Saint-Germain
75007 Paris
France
Manufacturer:
Laboratoires MACORS
22 rue des Caillotes
89000 Auxerre
France
For further information about this medicinal product, please contact the local representative of the marketing authorization holder:
Nordic Pharma S.A.U.
Adolfo Perez Esquivel 3, 2nd floor, Office 17,
Las Americas III Building,
Parque Empresarial Las Rozas,
28232 Madrid, Spain
+34 916 404 041
This medicinal product is authorized in the Member States of the European Economic Area under the following name: MIFEGYNE
Date of the last revision of this leaflet:05/2021
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for MIFEGYNE 200 mg TABLETS – subject to medical assessment and local rules.